Hydroxamic Acid Derivatives as Potential Anticancer Agents
作者： Manish K. Gupta , Gagandip Singh , Swati Gupta
DOI: 10.1007/978-3-642-38111-9_7
关键词: TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME 、 Histone deacetylase 、 Hydroxamic acid 、 Enzyme 、 Human epidermal growth factor 、 Biochemistry 、 Matrix metalloproteinase 、 Chemistry 、 Organic molecules 、 Chelation
摘要: Hydroxamic acid containing organic molecules display strong metal ion chelating property, and therefore used as metalloenzyme inhibitors. They affinity toward histone deacetylase, matrix metalloproteinases, human epidermal growth factor receptor-2, tumor necrosis alpha converting enzyme. These enzymes play crucial roles in the pathogenesis of cancer are attractive targets for development new anticancer agents. Various bearing free hydroxamic at one terminal have been synthesized evaluated their activities. This article will focus on various classes acid-based inhibitors
springer.com
sci-hub.st 参考文章(108)
Michael F Press, Heinz-Josef Lenz, EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. ,vol. 67, pp. 2045- 2075 ,(2007) , 10.2165/00003495-200767140-00006
S Curran, G.I Murray, Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. European Journal of Cancer. ,vol. 36, pp. 1621- 1630 ,(2000) , 10.1016/S0959-8049(00)00156-8
Chemical Reactivity Theory : A Density Functional View CRC Press. ,(2009) , 10.1201/9781420065442
Andrew W. Millar, Peter D. Brown, Jeff Moore, W. Alan Galloway, Alan G. Cornish, Terence J. Lenehan, Kevin P. Lynch, Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers British Journal of Clinical Pharmacology. ,vol. 45, pp. 21- 26 ,(1998) , 10.1046/J.1365-2125.1998.00639.X
M Yoshida, M Kijima, M Akita, T Beppu, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. Journal of Biological Chemistry. ,vol. 265, pp. 17174- 17179 ,(1990) , 10.1016/S0021-9258(17)44885-X
Bernard Barlaam, T. Geoffrey Bird, Christine Lambert-van der Brempt, Douglas Campbell, Steve J. Foster, Rose Maciewicz, New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. Journal of Medicinal Chemistry. ,vol. 42, pp. 4890- 4908 ,(1999) , 10.1021/JM990377J
M Kijima, M Yoshida, K Sugita, S Horinouchi, T Beppu, Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. Journal of Biological Chemistry. ,vol. 268, pp. 22429- 22435 ,(1993) , 10.1016/S0021-9258(18)41547-5
R B Dickson, M D Johnson, E A Bone, J A Low, The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clinical Cancer Research. ,vol. 2, pp. 1207- 1214 ,(1996)
Amy R. Nelson, Barbara Fingleton, Mace L. Rothenberg, Lynn M. Matrisian, Matrix Metalloproteinases: Biologic Activity and Clinical Implications Journal of Clinical Oncology. ,vol. 18, pp. 1135- 1135 ,(2000) , 10.1200/JCO.2000.18.5.1135
Nicholas B La Thangue, Jane A Plumb, Robert Brown, Robert J Williams, Paul W Finn, Claire J Watkins, M Rosario Romero, Morwenna J Bandara, Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 Molecular Cancer Therapeutics. ,vol. 2, pp. 721- 728 ,(2003)